 PARIS CHICAGO CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen Euronext: IPN; ADR: IPSEY and Exicure Inc. NASDAQ: XCUR have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids SNAs as potential investigational treatments for Huntingtons disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used 